TY - JOUR T1 - From the Authors JF - European Respiratory Journal JO - Eur Respir J SP - 330 LP - 331 DO - 10.1183/09031936.04.00043804 VL - 24 IS - 2 AU - G. Hanf AU - O. Noga Y1 - 2004/08/01 UR - http://erj.ersjournals.com/content/24/2/330.2.abstract N2 - From the authors: In our recent article, we demonstrated the inhibitory effect of subcutaneously administered monoclonal anti-immunoglobulin‐E antibody, omalizumab, on nasal responses to allergen challenge in patients with allergic rhinitis 1. Omalizumab-treated patients showed reduced nasal symptoms, an inhibition of the increase of human serum albumin the nasal lavage fluid after allergen challenge and a decrease in tumour necrosis factor‐α in basal nasal lavage fluids. D.K.C. Lee mentioned in his Letter to the Editor, that no exact degree of disease severity and no data with regards to the usual therapy for allergic rhinitis were given in the article. Moreover, D.K.C. Lee … ER -